NCT02981719

Simultaneous Gemcitabine and Irreversible Electroporation for Locally Advanced Pancreatic Cancer

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 61 (actual)
• Sponsor: Fuda Cancer Hospital, Guangzhou · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The aim of this study was to compare the therapeutic efficacy between simultaneous gemcitabine administration and IRE and IRE alone for locally advanced pancreatic cancer (LAPC)

Detailed description

in the GEM- IRE group, before the IRE ablation started, patients received 1000 mg/m2 gemcitabine hydrochloride \[Qilu pharmaceutical (Hainan) Co., Ltd. Haikou, China\] intravenously (over approximately 30 min). In the IRE group, the IRE ablation was performed without gemcitabine intravenous infusion before IRE. The aim of this study was to evslusted the overall survival (OS), objective response rate (ORR) and adverse events after simultaneous therapy.

Conditions

• Pancreatic Cancer

Interventions

Type	Name	Description
PROCEDURE	simultaneous gemcitabine and irreversible electroporation	gemcitabine intravenous infusion prior to irreversible electroporation treatment
PROCEDURE	irreversible electroporation	percutaneous irreversible electroporation was performmed for locally advaanced pancreatic cancer.

Timeline

• Start date: 2016-10-01
• Primary completion: 2018-10-01
• Completion: 2020-10-01
• First posted: 2016-12-05
• Last updated: 2021-01-22

Locations

1 site across 1 country: China